AR117565A1 - Agentes de unión a c3 y método de uso de los mismos - Google Patents

Agentes de unión a c3 y método de uso de los mismos

Info

Publication number
AR117565A1
AR117565A1 ARP190100853A ARP190100853A AR117565A1 AR 117565 A1 AR117565 A1 AR 117565A1 AR P190100853 A ARP190100853 A AR P190100853A AR P190100853 A ARP190100853 A AR P190100853A AR 117565 A1 AR117565 A1 AR 117565A1
Authority
AR
Argentina
Prior art keywords
binding agents
same
encode
antibodies
compositions
Prior art date
Application number
ARP190100853A
Other languages
English (en)
Inventor
Wenwu Zhai
Yiyuan Yin
Yan Wang
Jie Tang
Zhonghao Liu
Jared Martin Higbee
Dana Yen Mei Duey
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of AR117565A1 publication Critical patent/AR117565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente divulgación proporciona agentes de unión, como por ej, anticuerpos (que incluyen los fragmentos variables de cadena simple), que se unen específicamente al componente complemento C3, que incluyen el C3 humano, las composiciones que comprenden los mismos, y los métodos para su uso. La divulgación, además, proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que comprenden a estos.
ARP190100853A 2018-04-03 2019-04-01 Agentes de unión a c3 y método de uso de los mismos AR117565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862652253P 2018-04-03 2018-04-03

Publications (1)

Publication Number Publication Date
AR117565A1 true AR117565A1 (es) 2021-08-18

Family

ID=66630340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100853A AR117565A1 (es) 2018-04-03 2019-04-01 Agentes de unión a c3 y método de uso de los mismos

Country Status (17)

Country Link
US (3) US11136381B2 (es)
EP (1) EP3790897A1 (es)
JP (2) JP7477457B2 (es)
KR (1) KR20200138290A (es)
CN (1) CN112105638A (es)
AR (1) AR117565A1 (es)
AU (1) AU2019248557A1 (es)
BR (1) BR112020019907A2 (es)
CA (1) CA3093356A1 (es)
CL (2) CL2020002522A1 (es)
CO (1) CO2020013468A2 (es)
IL (1) IL277404A (es)
MX (1) MX2020010323A (es)
PE (1) PE20212132A1 (es)
PH (1) PH12020500664A1 (es)
SG (1) SG11202008897SA (es)
WO (1) WO2019195136A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200138290A (ko) 2018-04-03 2020-12-09 엔지엠 바이오파마슈티컬스, 아이엔씨. C3-결합제 및 이의 사용 방법
WO2021226442A2 (en) * 2020-05-08 2021-11-11 Ngm Biopharmaceuticals, Inc. Therapeutic uses of c3-binding agents
US20230381269A1 (en) * 2020-09-21 2023-11-30 Apellis Pharmaceuticals, Inc. Methods of treating eye disorders
WO2023118312A1 (en) 2021-12-22 2023-06-29 Cdr-Life Ag Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CN117447601B (zh) * 2023-12-22 2024-03-08 北京索莱宝科技有限公司 猪IgM的抗体、抗体组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141936A0 (en) * 1998-09-10 2002-03-10 Univ Virginia Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells
WO2004031240A1 (en) 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
AU2003286004A1 (en) * 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2006012621A2 (en) 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2006083533A2 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MY151064A (en) 2005-11-04 2014-03-31 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
ES2545775T3 (es) 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
JP5653214B2 (ja) 2009-05-20 2015-01-14 東レ株式会社 細胞膜透過性ペプチド
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
US20130177567A1 (en) 2010-05-18 2013-07-11 Sydansk Universitet Novel c3c epitope, antibodies binding thereto, and use thereof
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
US9243060B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized anti-factor C3b antibodies and uses thereof
CA2934462A1 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
JP6598798B2 (ja) 2014-05-05 2019-10-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃ５およびｃ３動物
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2017048466A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Compositions and methods for delivering biotherapeutics
CN108431019A (zh) 2015-10-07 2018-08-21 阿佩利斯制药有限公司 给药方案
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
KR20200138290A (ko) 2018-04-03 2020-12-09 엔지엠 바이오파마슈티컬스, 아이엔씨. C3-결합제 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2019248557A1 (en) 2020-09-24
US11136381B2 (en) 2021-10-05
CN112105638A (zh) 2020-12-18
TW202003559A (zh) 2020-01-16
JP2024056851A (ja) 2024-04-23
PH12020500664A1 (en) 2021-06-07
WO2019195136A1 (en) 2019-10-10
MX2020010323A (es) 2021-01-08
US20220119508A1 (en) 2022-04-21
CO2020013468A2 (es) 2020-11-10
RU2020135712A (ru) 2022-05-04
BR112020019907A2 (pt) 2021-01-05
CA3093356A1 (en) 2019-10-10
IL277404A (en) 2020-11-30
SG11202008897SA (en) 2020-10-29
EP3790897A1 (en) 2021-03-17
PE20212132A1 (es) 2021-11-05
US11767359B2 (en) 2023-09-26
JP2021520195A (ja) 2021-08-19
JP7477457B2 (ja) 2024-05-01
CL2021002039A1 (es) 2022-04-01
CL2020002522A1 (es) 2021-02-26
KR20200138290A (ko) 2020-12-09
US20230382985A1 (en) 2023-11-30
US20190322730A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CO2018000992A2 (es) Anticuerpos anti-pd-1 novedosos
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
CL2020001854A1 (es) Anticuerpos de unión a gprc5d.
CO2017012342A2 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit)
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CO2017001558A2 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CO2021013279A2 (es) Anticuerpos de cadena pesada que se unen al psma
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CO2020008925A2 (es) Anticuerpos de cadena pesada que se unen a cd22
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
ECSP22041860A (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
UY36706A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CL2020001629A1 (es) Anticuerpos de unión a hla-a2/wt1.